Related Experiment Videos
[PI3K-AKT-mTOR pathway inhibitors].
Alexis Cortot1, Jean-Pierre Armand, Jean-Charles Soria
1Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulin, 94805 Villejuif.
Bulletin Du Cancer
|February 4, 2006
Summary
Molecular targeted agents, including signal transduction inhibitors, offer new anti-cancer strategies. This review focuses on the PI3K-AKT-mTOR pathway and its inhibition in cancers, particularly with mTOR inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Molecular targeted agents are expanding cancer treatment options.
- Signal transduction inhibitors show promise in anti-cancer therapy.
- The PI3K-AKT-mTOR pathway is frequently dysregulated in human cancers.
Purpose of the Study:
- To provide an overview of the PI3K-AKT-mTOR pathway.
- To discuss the targeting of this pathway in human malignancies.
- To focus on mechanistic target of rapamycin (mTOR) inhibitors.
Main Methods:
- Literature review of PI3K-AKT-mTOR pathway.
- Analysis of targeting strategies in cancer.
- Review of mTOR inhibitors' role.
Main Results:
- The PI3K-AKT-mTOR pathway is a critical regulator of cell growth and survival.
- Alterations in this pathway are common across various cancers.
- mTOR inhibitors represent a significant therapeutic approach.
Conclusions:
- Targeting the PI3K-AKT-mTOR pathway is a viable anti-cancer strategy.
- mTOR inhibitors are a key component of this therapeutic approach.
- Further research into pathway modulation holds promise for improved cancer treatment.